2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
11.17.16
Catabasis Pharmaceuticals Provides Edasalonexent and Rare Disease Pipeline Updates at Investor Day
11.10.16
Catabasis Pharmaceuticals Reports Third Quarter 2016 Financial Results and Recent Corporate Highlights
11.03.16
Catabasis Pharmaceuticals to Host Investor Day in New York City on November 17
10.27.16
Catabasis Pharmaceuticals Presents Positive Data for CAT-5571, a Novel Activator of Autophagy, as a Potential Oral Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
10.26.16
Catabasis Pharmaceuticals to Report Third Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, November 10
10.20.16
Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 30th Annual North American Cystic Fibrosis Conference
10.11.16
Catabasis Pharmaceuticals to Present the MoveDMD® Trial of Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy for DMD, at the American Neurological Association’s 2016 Annual Meeting
10.06.16
Catabasis Pharmaceuticals Presents Positive Data from Part A of the MoveDMD® Trial of Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy for DMD, at the World Muscle Society Congress
10.05.16
Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen to Senior Vice President of Product Development
10.04.16
Catabasis Pharmaceuticals Completes Target Enrollment for Part B of the MoveDMD® Trial, a Phase 2 Trial of Edasalonexent (CAT-1004) for the Potential Treatment of Duchenne Muscular Dystrophy
09.29.16
Catabasis Pharmaceuticals and Sarepta Therapeutics Announce a Joint Research Collaboration in Duchenne Muscular Dystrophy
09.28.16
Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
09.23.16
Catabasis Pharmaceuticals Announces Pricing of $10 Million Offering of Common Stock
08.11.16
Catabasis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights
08.09.16
Catabasis Pharmaceuticals to Present at 2016 Wedbush PacGrow Healthcare Conference
07.28.16
Catabasis Pharmaceuticals to Report Second Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, August 11
07.12.16
Catabasis Pharmaceuticals Names Joseph Johnston VP, Regulatory Affairs
07.07.16
Catabasis Pharmaceuticals Announces the Initiation of an Open-Label Extension for the MoveDMD® Trial Studying Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
06.20.16
Catabasis Pharmaceuticals to Present Edasalonexent (CAT-1004), an Oral Agent Targeting NF-kB: MoveDMDSM Trial in Duchenne Muscular Dystrophy (DMD) at the 2016 PPMD Annual Connect Conference
06.08.16
Catabasis Pharmaceuticals and Parent Project Muscular Dystrophy to Host a Webinar on MoveDMDSM: A Clinical Trial of Edasalonexent (CAT-1004) in Boys with Duchenne Muscular Dystrophy
06.07.16
Catabasis Pharmaceuticals Announces Top-Line Phase 2a Results for CAT-2054
05.21.16
Catabasis Pharmaceuticals Presents Positive Pre-Clinical Data at Digestive Disease Week 2016; Data Support CAT-2054, a Phase 2 Asset, as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH)
05.16.16
Catabasis Pharmaceuticals to Present Pre-Clinical Data Supporting CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) at Digestive Disease Week 2016
05.16.16
Catabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions
05.12.16
Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights
04.28.16
Catabasis Pharmaceuticals to Report First Quarter 2016 Financial Results and Recent Corporate Developments on Thursday, May 12
04.12.16
Catabasis Pharmaceuticals Initiates Part B of the MoveDMDSM Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
04.07.16
Catabasis Pharmaceuticals to Present at Needham and Company’s 15th Annual Healthcare Conference
04.06.16
Catabasis Pharmaceuticals Announces Additions to Board of Directors and the Formation of a Science and Technology Committee
04.01.16
Catabasis Pharmaceuticals Announces Resignation of Chief Financial Officer
03.21.16
Catabasis Pharmaceuticals Presents Positive CAT-1004 Data from Part A of the MoveDMDSM Trial at the 2016 Muscular Dystrophy Association Clinical Conference
03.18.16
Catabasis Pharmaceuticals to Present CAT-1004 Data from Part A of the MoveDMDSM Trial at the 2016 Muscular Dystrophy Association Clinical Conference
03.02.16
Catabasis Pharmaceuticals to Present at Cowen and Company’s 36th Annual Health Care Conference
03.02.16
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Developments
02.17.16
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Financial Results and Recent Corporate Developments on Wednesday, March 2
02.10.16
Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
02.05.16
Muscular Dystrophy Association to Collaborate with Catabasis Pharmaceuticals on Development of CAT-1004, a Potential Novel Oral Disease-Modifying Treatment for Duchenne Muscular Dystrophy
01.25.16
Catabasis Pharmaceuticals Announces Positive Top-Line Results from Part A of the MoveDMD℠ Trial, a Phase 1 / 2 Trial of CAT-1004 for the Treatment of Duchenne Muscular Dystrophy
01.19.16
FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich’s Ataxia
The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions. There are a number of important factors that could cause Catabasis’ actual results to differ materially from those indicated by such forward-looking statements, including factors identified in the company’s most recent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.